Clinical efficacy of Atezolizumab/Bevacizumab combined with TACE in treating BCLC stage C hepatocellular carcinoma
Frontiers in Oncology · 19.03.2026 · 16
DOI: 10.3389/fonc.2026.1744076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 19.03.2026. Verfasst von Lei Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatic Surgery and Liver Transplantation, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The prognosis of advanced primary liver cancer [Barcelona Clinic Liver Cancer (BCLC) stage C] remains poor. Although atezolizumab plus bevacizumab (Ate/Bev) is a standard treatment, the potential of intensifying this regimen into a triple therapy by adding local intervention is unclear.
Aim
To evaluate the efficacy of Ate/Bev plus transarterial chemoembolisation (TACE) in the treatment of BCLC stage C advanced hepatocellular carcinoma (HCC).
Methods
The clinical data of 25 patients with BCLC-C HCC treated with Ate/Bev plus TACE at Guangdong Provincial Traditional Chinese Medicine Hospital between January 2022 and October 2024 were retrospectively analyzed. Efficacy was evaluated using Response Evaluation Criteria in Solid Tumors version 1.1, with follow-up until April 2025. The primary endpoints included the objective response rate, disease control rate, progression-free survival (PFS), and safety.
Results
Of the 33 patients with intermediate-/advanced-stage HCC receiving the triple therapy, 25 were categorized as BCLC stage C HCC. Twelve patients died, and thirteen survived, during follow-up. The objective response rate was 32%, PFS was 7.960 ± 6.624 months, and overall survival (OS) was 12.880 ± 7.769 months. OS and PFS significantly differed by the neutrophil-to-lymphocyte ratio (≥ 3 vs < 3). The hazard ratios for median PFS and median OS were significantly different (P < 0.005) between the two groups, at 2.004 (95% confidence interval: 1.86–3.74) and 1.765 (95% confidence interval: 1.24–3.06), respectively. The incidence of all-grade adverse reactions was 100%, with grade 3/4 events seen in 4% of patients. No treatment-related deaths occurred.
Conclusion
Atezolizumab combined with bevacizumab and TACE may be safe and effective in the treatment of BCLC stage C hepatocellular carcinoma. Baseline NLR may be an important potential biomarker for predicting the efficacy and prognosis of such patients. However, the above conclusions still need to be further verified by large-sample prospective randomized controlled trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatic Surgery and Liver Transplantation, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China.
- Department of Hepatic Surgery and Liver Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Zitieren
APA
Yuan, L., Yang, X. H., Ma, Z. L., Fan, N., Wang, G. S., & Zhu, Y. L. (2026). Clinical efficacy of Atezolizumab/Bevacizumab combined with TACE in treating BCLC stage C hepatocellular carcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1744076
Vancouver
Yuan L, Yang XH, Ma ZL, Fan N, Wang GS, Zhu YL. Clinical efficacy of Atezolizumab/Bevacizumab combined with TACE in treating BCLC stage C hepatocellular carcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1744076
BibTeX
@article{Yuan2026,
author = {Yuan, Lei and Yang, Xiao-Hong and Ma, Zhi-Li and Fan, Ning and Wang, Gen-Shu and Zhu, Yan-Ling},
title = {Clinical efficacy of Atezolizumab/Bevacizumab combined with TACE in treating BCLC stage C hepatocellular carcinoma},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1744076}
}
EUVIMED